Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL19534323 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29367581 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501478 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| CN-110475571-B | Replacement for cellular immunotherapy pre-conditioning for cytotoxicity | AVM生物技术有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20210244854-A1 | EXPANDABLE BONE AND TISSUE REGENERATION SYSTEM, AND APPLICATIONS OF SAME | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-08-12 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3621633-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-110475571-A | The substitution of cytotoxicity preconditioned before cellular immunotherapy | AVM BIOTECHNOLOGY LLC | 2019-11-19 | — | — | CN | disclosed |
| EP-3479818-A1 | LONG ACTING INJECTABLE PARASITICIDAL FORMULATIONS | Merial, Inc. (US) | 2019-05-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190022279-A1 | TUNABLE POROUS 3D BIODEGRADABLE, BIOCOMPATIBLE POLYMER/NANOMATERIAL SCAFFOLDS, AND FABRICATING METHODS AND APPLICATIONS OF SAME | UNITED STATES GOVERNMENT | 2019-01-24 | — | — | US | disclosed |
| WO-2018208954-A2 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-6602879-B2 | For inhibiting the replication or infectivity of a virus; therapy | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-08-05 | — | — | US | disclosed |
| US-20030119894-A1 | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells | GEMIN X BIOTECHNOLOGIES INC. | 2003-06-26 | — | — | US | disclosed |
| US-6583309-B1 | Such as 1-(5-Amino-1-(3-(1-aminomethyl-4-guanidino-butyl)-ureidomethyl)-pentyl)-3-(5-guanidino-2-ureido-pentyl)-urea | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2003-06-24 | — | — | US | disclosed |
| WO-2003015788-A1 | METHODS FOR TREATMENT OF PREVENTION OF CANCER OR NEOPLASTIC DISEASES | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003008410-A2 | POLYPYRROLES AS AGENTS FOR TREATING CANCER, TREATING VIRAL DISEASES AND CAUSING IMMUNOSUPPRESSION | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2003-01-30 | — | — | WO | disclosed |
| EP-1226115-A1 | NOVEL CARBAMATES AND UREAS | University of Medicine and Dentistry of New Jersey (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6420591-B1 | ANTICARCINOGENIC AGENTS AND VIRICIDES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2002-07-16 | — | — | US | disclosed |
| US-6407244-B1 | ANTIPROLIFERATIVE AGENT | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2002-06-18 | — | — | US | disclosed |
| WO-2001025188-A1 | NOVEL CARBAMATES AND UREAS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119894-A1 | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells | BAX, BCL2, BCL2L11 | TOP1 198/4885GLA 2664/4885GAA 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.